During the 2022 SOHO Annual Meeting, Jacqueline S. Garcia, MD, discussed immunotherapies for myelodysplastic syndromes.
Dr. Garcia Discusses Immune Therapy Approaches in MDS
By Kerri Fitzgerald - Last Updated: November 15, 2022Related Posts
This life-threatening pediatric disease can cause sideroblastic anemia, metabolic crisis, and bone marrow failure.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
ELEMENT-MDS trial tests luspatercept vs epoetin alfa for anemia in ESA-naive, lower-risk MDS without transfusion need.
Our expert roundtable reacts to data presented at ASCO 2025 on real-world use of the agent in this setting.
Experts discuss what data do clinicians need in order to optimize their first-line use of this agent for low-risk MDS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.